Image

Melanoma Research

Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Blog - Melanoma360
Melanoma Research
Featured image for “A Letter From Our Vice President | January 2023”
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Blog - Melanoma360
Melanoma Research
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Blog - Melanoma360
Melanoma Research
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Blog - Melanoma360
Melanoma Research
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Blog - Melanoma360
Breaking News
Melanoma Research
Featured image for “Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center”
05/25/2022

Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center

Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
Blog - Melanoma360
Melanoma Research
Featured image for “FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium”
05/25/2022

FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium

TISSUE IS THE ISSUE AIM at Melanoma’s major research initiative—the International Melanoma Tissue Bank Consortium (IMTBC)—is the first of its…
Blog - Melanoma360
Melanoma Research
Featured image for “COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma”
05/25/2022

COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma

By Erin Bekes In a study by Dr. Antoine Eskander and colleagues described in the Journal of the National Comprehensive…
Blog - Melanoma360
Melanoma Research
Featured image for “FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients”
12/04/2021

FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients

  December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
Blog - Melanoma360
Breaking News
Melanoma Research
01/27/2023

Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?

By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory In January 2022, tebentafusp-tebn, also known under the more easily pronounceable…
Featured image for “Notes from the Lab: T-Cell Engagers, the Next Stage in Cancer Immunotherapy?”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

A Letter From Our Vice President | January 2023

  Happy new year to you and your families! I hope that 2023 has started well for you. Before I…
Featured image for “A Letter From Our Vice President | January 2023”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium

This article is an update of an article we published last year. AIM at Melanoma’s major research initiative—the International Melanoma…
Featured image for “TISSUE IS THE ISSUE—2023 Update on AIM’s International Melanoma Tissue Bank Consortium”
Blog - Melanoma360
 | 
Melanoma Research
01/26/2023

What Makes AIM’s IMTBC Even More Valuable

AIM at Melanoma’s major research project, the International Melanoma Tissue Bank Consortium (IMTBC), is the first collaborative fresh frozen primary…
Featured image for “What Makes AIM’s IMTBC Even More Valuable”
Blog - Melanoma360
 | 
Melanoma Research
12/08/2022

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

December 07, 2022 07:00 ET | Source: Replimune Group Inc RP1 combined with nivolumab continues to demonstrate deep and durable responses in…
Featured image for “Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
11/11/2022

Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting

(November 07, 2022 08:01 ET | Source: Iovance Biotherapeutics, Inc. ) Clinically Meaningful and Durable Activity in Largest Cell Therapy…
Featured image for “Iovance Biotherapeutics Announces Updated Clinical Data for Lifileucel in Advanced Melanoma at Society for Immunotherapy of Cancer (SITC) Annual Meeting”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research
05/25/2022

Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center

Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
Featured image for “Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center”
Blog - Melanoma360
 | 
Melanoma Research
05/25/2022

FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium

TISSUE IS THE ISSUE AIM at Melanoma’s major research initiative—the International Melanoma Tissue Bank Consortium (IMTBC)—is the first of its…
Featured image for “FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium”
Blog - Melanoma360
 | 
Melanoma Research
05/25/2022

COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma

By Erin Bekes In a study by Dr. Antoine Eskander and colleagues described in the Journal of the National Comprehensive…
Featured image for “COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma”
Blog - Melanoma360
 | 
Melanoma Research
12/04/2021

FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients

  December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
Featured image for “FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients”
Blog - Melanoma360
 | 
Breaking News
 | 
Melanoma Research